Schenk Ina, Machnik Marc, Broussou Diane, Meuly Astrid, Roques Béatrice B, Lallemand Elodie, Düe Michael, Röttgen Helma, Lagershausen Henrike, Toutain Pierre-Louis, Thevis Mario
Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany.
INTHERES, INRAE, ENVT, Université de Toulouse, Toulouse, France.
J Vet Pharmacol Ther. 2021 Sep;44(5):733-744. doi: 10.1111/jvp.12991. Epub 2021 Jun 11.
In horses, the benzodiazepine diazepam (DIA) is used as sedative for pre-medication or as an anxiolytic to facilitate horse examinations. As the sedative effects can also be abused for doping purposes, DIA is prohibited in equine sports. DIA is extensively metabolized to several active metabolites such as nordazepam, temazepam and oxazepam (OXA). For veterinarians, taking into account the detection times of DIA and its active metabolites is needed for minimizing the risk of an anti-doping rule violation. Therefore, a pharmacokinetic study on 6 horses was conducted using a single intravenous (IV) dose of 0.2 mg/kg DIA Plasma and urine samples were collected at specified intervals until 16 and 26 days post-administration, respectively. Samples were analysed by a sensitive liquid chromatography-electrospray ionization/tandem mass spectrometry method. DIA showed a triphasic elimination pattern in the horse. The mean plasma clearance of DIA was 5.9 ml/min/kg, and the plasma elimination half-life in the terminal phase was 19.9 h. Applying the Toutain model approach, an effective plasma concentration of DIA was estimated at 24 ng/ml, and irrelevant plasma concentration (IPC) and irrelevant urine concentration (IUC) were computed to 0.047 and 0.1 ng/ml, respectively. The detection time according to the European Horserace Scientific Liaison Committee (EHSLC), that is the time for which observed DIA plasma concentrations of all investigated horses were below the IPC was 10 days. Using Monte Carlo Simulations, it was estimated that concentrations of DIA in plasma would fall below the IPC 18 days after the DIA administration for 90% of horses. However, in the present study, a single administration of DIA could be detected for 24 days in urine via the presence of OXA, its dominant metabolite.
在马匹中,苯二氮䓬类药物地西泮(DIA)用作术前镇静剂或抗焦虑药以方便对马匹进行检查。由于其镇静作用也可能被滥用于兴奋剂目的,DIA在马术运动中被禁止使用。DIA会广泛代谢为多种活性代谢物,如去甲地西泮、替马西泮和奥沙西泮(OXA)。对于兽医而言,需要考虑DIA及其活性代谢物的检测时间,以尽量降低违反反兴奋剂规则的风险。因此,对6匹马进行了一项药代动力学研究,静脉注射单次剂量为0.2mg/kg的DIA。分别在给药后16天和26天内按指定间隔采集血浆和尿液样本。通过灵敏的液相色谱 - 电喷雾电离/串联质谱法对样本进行分析。DIA在马体内呈现三相消除模式。DIA的平均血浆清除率为5.9ml/min/kg,终末相的血浆消除半衰期为19.9小时。应用图坦模型方法,估计DIA的有效血浆浓度为24ng/ml,无关血浆浓度(IPC)和无关尿液浓度(IUC)分别计算为0.047和0.1ng/ml。根据欧洲赛马科学联络委员会(EHSLC)的规定,检测时间即所有受试马匹的DIA血浆浓度低于IPC的时间为10天。使用蒙特卡洛模拟估计,对于90%的马匹,DIA给药后18天血浆中DIA浓度将降至IPC以下。然而,在本研究中,通过其主要代谢物OXA的存在,单次给药的DIA在尿液中可被检测到24天。